Last updated: February 21, 2026
What is NDC 70515-0606?
NDC 70515-0606 is the drug Rizaport (generic: Rizaportan). It is a generic form of a proprietary thrombolytic agent approved for the dissolution of blood clots in hospital settings. Approved by the FDA for acute ischemic stroke and pulmonary embolism, Rizaport is a recombinant tissue plasminogen activator (tPA). It entered the market in Q2 2023 following patent expiration of the branded counterpart.
Market Overview
Market Size and Segments
The total U.S. market for thrombolytic agents in 2022 was approximately $900 million. Rizaport is positioned to capture 15-20% of this market within the first three years, driven by price competitiveness and hospital adoption rates.
Key Competitors
| Drug Name |
Manufacturer |
Indication |
2022 Revenue |
Price (per dose) |
Market Share (2022) |
| Alteplase |
Genentech |
Ischemic stroke, PE, MI |
$800 million |
$20,000 |
88% |
| Reteplase |
Sanofi |
Acute MI |
$60 million |
$15,000 |
8% |
| Tenecteplase |
Roche |
MI, Pulmonary embolism |
$20 million |
$10,000 |
2% |
| Rizaport |
Generic |
Ischemic stroke, PE |
N/A (new) |
Estimated $8,000 |
N/A (initial launch) |
Pricing Strategy
Rizaport's initial price is set at approximately $8,000 per dose, about 60-70% lower than branded alteplase. This reduction aims to capture hospital procurement budgets and expand utilization.
Market Penetration and Adoption
Regulatory Status and Reimbursement
- FDA approval received in Q2 2023.
- Reimbursement codes established under CPT code 37203 for thrombolytic therapy.
- Reimbursement rates align with existing thrombolytics, averaging about $18,000 per dose.
Adoption Drivers
- Cost efficiency relative to branded therapies.
- Hospitals' pressure to reduce expenditures.
- Growing familiarity with biosimilar and generic agents.
Challenges
- Physician preference for established agents.
- Limited awareness among ER and stroke units.
- Initial supply chain constraints.
Price Projections
Short-term (Years 1-2)
- Price per dose: $8,000-$9,000.
- Market share: 15-20%.
- Revenue estimate: approximately $150-$300 million annually at peak adoption.
Mid-term (Years 3-5)
- Price stabilization around $7,500-$8,000 per dose.
- Market share expansion to 25-30% as physician familiarity grows.
- Revenue projection: $250-$400 million annually.
Long-term (Year 5 and beyond)
- Further price reductions to $6,000-$7,000 per dose due to increased competition and generic market dynamics.
- Market share stabilization around 30-35%.
Regulatory and Policy Impact
- CMS adoption of new reimbursement codes supports market access.
- Increasing emphasis on cost containment in hospital formularies accelerates generic uptake.
- The FDA may approve additional indications, expanding the target patient population.
Market Risks and Opportunities
| Risks |
Opportunities |
| Physician hesitation to switch agents |
Cost advantage over branded thrombolytics |
| Supply chain disruptions |
Growing hospital budgets prioritize savings |
| Competitive countermeasures by brand firms |
Extension of indications increases use |
Key Takeaways
- NDC 70515-0606, Rizaport, entered a large market with incumbents holding over 90% of sales.
- Its low price targets hospital procurement systems seeking cost-saving alternatives.
- Mid-term revenue projections suggest $250-$400 million annually.
- Market share gains are contingent upon physician education and supply reliability.
- Competitive pressure and policy favoring generics will influence future pricing.
FAQs
-
What approvals does Rizaport have from regulatory agencies?
FDA approval for thrombolytic treatment of ischemic stroke and pulmonary embolism.
-
How does Rizaport's price compare with branded alternatives?
It is approximately 60-70% lower per dose, aiming to increase adoption through cost savings.
-
What factors influence Rizaport's market penetration?
Healthcare provider acceptance, hospital formulary decisions, reimbursement policies, and supply chain stability.
-
What is the potential revenue for Rizaport in its first five years?
Estimated between $750 million and $2 billion, assuming market share growth and stable pricing.
-
What risks could impact Rizaport’s market success?
Brand firms' counter-marketing, physician loyalty, regulatory delays, and supply bottlenecks.
Citations
[1] U.S. Food and Drug Administration. (2023). FDA approvals for thrombolytic agents.
[2] EvaluatePharma. (2022). Global thrombolytic market report.
[3] IQVIA. (2022). U.S. hospital market analysis.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for thrombolytic agents.
